Familial combined hyperlipidemia (FCH) is a very common dyslipidemic syndrome with a high social relevance, being strictly associated to the onset of coronary artery diseases. Although many of the metabolic and biochemical defects associated to this pathology are shared with other dislipidemic syndromes, the clinical picture of FCH is quite well defined. However, the genetic basis of FCH is still unclear, and although several putative genes have been described so far, it is commonly accepted that FCH genetics is complex and, overall, heterogeneous. Our research project aims at building the tools for the analysis of the gene expression profiles specific for patients affected by familial combined hyperlipidemia (FCH). To this means, we have exploited the DNA microarrays technology to compare the expression "profiles" of familial combined hyperlipidemia (FCH) patients with those of normal control individuals. We have carried out a first genome-wide scanning by analysing the gene expression profiles of a restricted number of FCH patients with microarrays containing 21,000 unique human gene sequences. Our preliminary results show that about 150 genes change significantly their expression levels in FCH patients, as compared to normal control individuals
Gene expression profile analysis by DNA microarrays in familial combined hyperlipidemia patients. (2006) 6, 95-96
MARTINELLI, ROSANNA;
2006-01-01
Abstract
Familial combined hyperlipidemia (FCH) is a very common dyslipidemic syndrome with a high social relevance, being strictly associated to the onset of coronary artery diseases. Although many of the metabolic and biochemical defects associated to this pathology are shared with other dislipidemic syndromes, the clinical picture of FCH is quite well defined. However, the genetic basis of FCH is still unclear, and although several putative genes have been described so far, it is commonly accepted that FCH genetics is complex and, overall, heterogeneous. Our research project aims at building the tools for the analysis of the gene expression profiles specific for patients affected by familial combined hyperlipidemia (FCH). To this means, we have exploited the DNA microarrays technology to compare the expression "profiles" of familial combined hyperlipidemia (FCH) patients with those of normal control individuals. We have carried out a first genome-wide scanning by analysing the gene expression profiles of a restricted number of FCH patients with microarrays containing 21,000 unique human gene sequences. Our preliminary results show that about 150 genes change significantly their expression levels in FCH patients, as compared to normal control individualsI documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
